Key result
Post-PCI bleeding on antiplatelet therapy reaches ~11% prevalence and is strongly associated with mortality.
Why the study?
Bleeding prevalence varies widely and significantly impacts mortality in patients with CAD undergoing PCI on antiplatelet therapy, highlighting the need to examine risk stratification and clinical consequences.
Bleeding after PCI on antiplatelet therapy is common and strongly associated with mortality, highlighting the need for risk stratification using tools like the ARC-HBR criteria.
Emphasizes bleeding risk stratification in PCI; leaves open whether mitigation improves survival.
This comprehensive review focuses on bleeding risk and outcomes in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) with antiplatelet therapy. Bleeding prevalence varies widely, ranging from 1% to 10% in clinical trials and 2.8% to 11% in real-world studies, with a significant impact on mortality. The Academic Research Consortium for High Bleeding Risk criteria are well-validated, classifying approximately 50% of patients as high bleeding risk, who subsequently experience higher post-PCI bleeding rates. Key risk factors include advanced age, chronic kidney disease, and multiple comorbidities. This review also explores bleeding event definitions, risk stratification methods, and the clinical consequences of bleeding. The strong association between bleeding and mortality after PCI underscores the importance of vigilant monitoring and tailored management strategies.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2025) conducted a review in Coronary artery disease. Antiplatelet therapy was evaluated on Bleeding risk and mortality. Bleeding prevalence in patients undergoing PCI on antiplatelet therapy ranges from 1% to 10% in clinical trials and 2.8% to 11% in real-world studies, and is strongly associated with mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: